Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Toxins (Basel) ; 13(4)2021 04 10.
Article in English | MEDLINE | ID: mdl-33920096

ABSTRACT

Chronic kidney disease (CKD) affects more than 10% of the world population and leads to excess morbidity and mortality (with cardiovascular disease as a leading cause of death). Vascular calcification (VC) is a phenomenon of disseminated deposition of mineral content within the media layer of arteries preceded by phenotypic changes in vascular smooth muscle cells (VSMC) and/or accumulation of mineral content within the atherosclerotic lesions. Medial VC results in vascular stiffness and significantly contributes to increased cardio-vascular (CV) morbidity, whereas VC of plaques may rather increase their stability. Mineral and bone disorders of CKD (CKD-MBD) contribute to VC, which is further aggravated by accumulation of uremic toxins. Both CKD-MBD and uremic toxin accumulation affect not only patients with advanced CKD (glomerular filtration rate (GFR) less than 15 mL/min./1.72 m2, end-stage kidney disease) but also those on earlier stages of a disease. The key uremic toxins that contribute to VC, i.e., p-cresyl sulphate (PCS), indoxyl sulphate (IS) and trimethylamine-N-oxide (TMAO) originate from bacterial metabolism of gut microbiota. All mentioned toxins promote VC by several mechanisms, including: Transdifferentiation and apoptosis of VSMC, dysfunction of endothelial cells, oxidative stress, interaction with local renin-angiotensin-aldosterone system or miRNA profile modification. Several attractive methods of gut microbiota manipulations have been proposed in order to modify their metabolism and to limit vascular damage (and VC) triggered by uremic toxins. Unfortunately, to date no such method was demonstrated to be effective at the level of "hard" patient-oriented or even clinically relevant surrogate endpoints.


Subject(s)
Bacteria/metabolism , Blood Vessels/metabolism , Chronic Kidney Disease-Mineral and Bone Disorder/metabolism , Gastrointestinal Microbiome , Intestines/microbiology , Renal Insufficiency, Chronic/metabolism , Toxins, Biological/metabolism , Uremia/metabolism , Vascular Calcification/metabolism , Animals , Blood Vessels/pathology , Chronic Kidney Disease-Mineral and Bone Disorder/microbiology , Disease Progression , Humans , Prognosis , Renal Insufficiency, Chronic/microbiology , Uremia/microbiology , Vascular Calcification/microbiology , Vascular Calcification/pathology
2.
Cardiovasc Res ; 117(2): 435-449, 2021 01 21.
Article in English | MEDLINE | ID: mdl-32267921

ABSTRACT

AIMS: The microbiome-derived metabolite trimethylamine-N-oxide (TMAO) has attracted major interest and controversy both as a diagnostic biomarker and therapeutic target in atherothrombosis. METHODS AND RESULTS: Plasma TMAO increased in mice on 'unhealthy' high-choline diets and notably also on 'healthy' high-fibre diets. Interestingly, TMAO was found to be generated by direct oxidation in the gut in addition to oxidation by hepatic flavin-monooxygenases. Unexpectedly, two well-accepted mouse models of atherosclerosis, ApoE-/- and Ldlr-/- mice, which reflect the development of stable atherosclerosis, showed no association of TMAO with the extent of atherosclerosis. This finding was validated in the Framingham Heart Study showing no correlation between plasma TMAO and coronary artery calcium score or carotid intima-media thickness (IMT), as measures of atherosclerosis in human subjects. However, in the tandem-stenosis mouse model, which reflects plaque instability as typically seen in patients, TMAO levels correlated with several characteristics of plaque instability, such as markers of inflammation, platelet activation, and intraplaque haemorrhage. CONCLUSIONS: Dietary-induced changes in the microbiome, of both 'healthy' and 'unhealthy' diets, can cause an increase in the plasma level of TMAO. The gut itself is a site of significant oxidative production of TMAO. Most importantly, our findings reconcile contradictory data on TMAO. There was no direct association of plasma TMAO and the extent of atherosclerosis, both in mice and humans. However, using a mouse model of plaque instability we demonstrated an association of TMAO plasma levels with atherosclerotic plaque instability. The latter confirms TMAO as being a marker of cardiovascular risk.


Subject(s)
Atherosclerosis/blood , Bacteria/metabolism , Choline/administration & dosage , Diet, Healthy , Dietary Fiber/administration & dosage , Gastrointestinal Microbiome , Methylamines/blood , Plaque, Atherosclerotic , Animal Feed , Animals , Atherosclerosis/diagnostic imaging , Atherosclerosis/microbiology , Atherosclerosis/pathology , Biomarkers/blood , Carotid Artery Diseases/blood , Carotid Artery Diseases/diagnostic imaging , Carotid Artery Diseases/microbiology , Choline/metabolism , Choline/toxicity , Coronary Artery Disease/blood , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/microbiology , Dietary Fiber/metabolism , Disease Models, Animal , Dysbiosis , Heart Disease Risk Factors , Humans , Male , Mice, Inbred C57BL , Mice, Knockout, ApoE , Receptors, LDL/genetics , Receptors, LDL/metabolism , Rupture, Spontaneous , Vascular Calcification/blood , Vascular Calcification/diagnostic imaging , Vascular Calcification/microbiology
3.
Cells ; 9(12)2020 12 15.
Article in English | MEDLINE | ID: mdl-33334022

ABSTRACT

Accumulating evidence suggests a link between periodontal disease and cardiovascular diseases. Vascular calcification is the pathological precipitation of phosphate and calcium in the vasculature and is closely associated with increased cardiovascular risk and mortality. In this study, we have demonstrated that the infection with Porphyromonas gingivalis (P. gingivalis), one of the major periodontal pathogens, increases inorganic phosphate-induced vascular calcification through the phenotype transition, apoptosis, and matrix vesicle release of vascular smooth muscle cells. Moreover, P. gingivalis infection accelerated the phosphate-induced calcium deposition in cultured rat aorta ex vivo. Taken together, our findings indicate that P. gingivalis contributes to the periodontal infection-related vascular diseases associated with vascular calcification.


Subject(s)
Muscle, Smooth, Vascular/pathology , Myocytes, Smooth Muscle/microbiology , Myocytes, Smooth Muscle/pathology , Phosphates/adverse effects , Porphyromonas gingivalis/physiology , Vascular Calcification/microbiology , Animals , Aorta/pathology , Apoptosis/drug effects , Calcium/metabolism , Cell Transdifferentiation/drug effects , Extracellular Matrix/metabolism , Male , Myocytes, Smooth Muscle/drug effects , Osteogenesis/drug effects , Rats, Sprague-Dawley
4.
Toxins (Basel) ; 12(5)2020 04 29.
Article in English | MEDLINE | ID: mdl-32365480

ABSTRACT

Patients with chronic kidney disease (CKD) are at increased risk of bone mineral density loss and vascular calcification. Bone demineralization and vascular mineralization often concur in CKD, similar to what observed in the general population. This contradictory association is commonly referred to as the 'calcification paradox' or the bone-vascular axis. Mounting evidence indicates that CKD-associated gut dysbiosis may be involved in the pathogenesis of the bone-vascular axis. A disrupted intestinal barrier function, a metabolic shift from a predominant saccharolytic to a proteolytic fermentation pattern, and a decreased generation of vitamin K may, alone or in concert, drive a vascular and skeletal pathobiology in CKD patients. A better understanding of the role of gut dysbiosis in the bone-vascular axis may open avenues for novel therapeutics, including nutriceuticals.


Subject(s)
Bacteria/metabolism , Bone Diseases, Metabolic/microbiology , Gastrointestinal Microbiome , Intestines/microbiology , Renal Insufficiency, Chronic/microbiology , Vascular Calcification/microbiology , Animals , Bone Density , Bone Diseases, Metabolic/physiopathology , Bone Diseases, Metabolic/prevention & control , Dysbiosis , Fermentation , Humans , Inflammation/microbiology , Prognosis , Renal Insufficiency, Chronic/physiopathology , Renal Insufficiency, Chronic/therapy , Risk Factors , Vascular Calcification/physiopathology , Vascular Calcification/prevention & control , Vitamin K Deficiency/microbiology
5.
Oxid Med Cell Longev ; 2019: 3415682, 2019.
Article in English | MEDLINE | ID: mdl-31007833

ABSTRACT

AIMS: Vascular calcification (VC) is a primary risk factor for cardiovascular mortality in chronic renal failure (CRF) patients; thus, effective therapeutic targets are urgently needed to be explored. Here, we identified the role of intestinal bacterial translocation in CRF-related VC. METHODS AND RESULTS: Antibiotic supplementation by oral gavage significantly suppressed intestinal bacterial translocation, CRF-related VC, and aortic osteogenic gene and Toll-like receptor (TLR) gene expression in CRF rats. Furthermore, TLR4 and TLR9 activation in vascular smooth muscle cells (VSMCs) aggravated inorganic phosphate- (Pi-) induced calcification. TLR9 inhibition, but not TLR4 inhibition, by both a pharmacological inhibitor and genetic methods could significantly reduce CRF rats' serum or CRF-induced VC. Interestingly, bone morphogenic protein-2 (BMP-2) levels were increased in the aorta and sera from CRF rats. Increased BMP-2 levels were also observed in VSMCs treated with TLR9 agonist, which was blocked by NF-κB inhibition. Both siRNA knockdown of BMP-2 and NF-κB inhibitor significantly blocked TLR9 agonist-induced VSMC calcification. CONCLUSIONS: Gut bacterial translocation inhibited by oral antibiotic significantly reduces CRF-related VC through inhibition of TLR9/NF-κB/BMP-2 signaling.


Subject(s)
Bacterial Translocation , Bone Morphogenetic Protein 2/metabolism , Gastrointestinal Microbiome , Toll-Like Receptor 9/metabolism , Vascular Calcification/metabolism , Vascular Calcification/microbiology , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacology , Bacterial Translocation/drug effects , Cell Differentiation/drug effects , DNA, Bacterial/metabolism , Gastrointestinal Microbiome/drug effects , Humans , Inflammation/pathology , Lipopolysaccharides/pharmacology , Male , Mice, Inbred C57BL , Muscle, Smooth, Vascular/pathology , Myocytes, Smooth Muscle/drug effects , Myocytes, Smooth Muscle/metabolism , NF-kappa B/metabolism , Osteoblasts/cytology , Rats, Wistar , Renal Insufficiency, Chronic/microbiology , Renal Insufficiency, Chronic/pathology , Signal Transduction
6.
J Cell Physiol ; 233(6): 4759-4769, 2018 06.
Article in English | MEDLINE | ID: mdl-29150938

ABSTRACT

Porphyromonas (P.) gingivalis infection leading to the periodontitis has been associated with the development of systemic diseases, including cardiovascular diseases and diabetes. However, the effect of a high concentration of glucose (HG) on the invasion efficiency of P. gingivalis and the consequent modulation of pathogenesis in vascular cells, especially in the vascular smooth muscle cells (VSMCs), remains unclear. Hence, the aim of this study was to investigate whether treating P. gingivalis with HG could change its invasion capability and result in VSMC calcification and the underlying mechanism. Human aortic SMCs (HASMCs) and P. gingivalis strain CCUG25226 were used in this study. We found that HGPg infection of HASMCs could initiate the HASMC calcification by stimulating the autocrine regulation of bone morphogenetic protein (BMP) 4 in HASMCs. The upregulation of BMP4 expression in HASMCs was mediated by toll-like receptor 4 and ERK1/2-p38 signaling after P. gingivalis infection. Moreover, the autocrine action of BMP4 in HGPg infection-initiated HASMC calcification upregulated BMP4-specific downstream smad1/5/8-runx2 signaling to increase the expressions of bone-related matrix proteins, that is, osteopontin, osteocalcin, and alkaline phosphatase. This study elucidates the detailed mechanism of HGPg infection-initiated calcification of HASMCs and indicates a possible therapeutic role of BMP4 in P. gingivalis infection-associated vascular calcification.


Subject(s)
Aortic Diseases/microbiology , Bacteroidaceae Infections/microbiology , Glucose/pharmacology , Muscle, Smooth, Vascular/microbiology , Myocytes, Smooth Muscle/microbiology , Osteogenesis , Porphyromonas gingivalis/drug effects , Vascular Calcification/microbiology , Aorta/metabolism , Aorta/microbiology , Aorta/pathology , Aortic Diseases/genetics , Aortic Diseases/metabolism , Aortic Diseases/pathology , Autocrine Communication , Bacteroidaceae Infections/metabolism , Bacteroidaceae Infections/pathology , Bone Morphogenetic Protein 4/genetics , Bone Morphogenetic Protein 4/metabolism , Cells, Cultured , Extracellular Signal-Regulated MAP Kinases/metabolism , Gene Expression Regulation , Host-Pathogen Interactions , Humans , Muscle, Smooth, Vascular/metabolism , Muscle, Smooth, Vascular/pathology , Myocytes, Smooth Muscle/metabolism , Myocytes, Smooth Muscle/pathology , Osteogenesis/genetics , Porphyromonas gingivalis/metabolism , Porphyromonas gingivalis/pathogenicity , Signal Transduction , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/metabolism , Vascular Calcification/genetics , Vascular Calcification/metabolism , Vascular Calcification/pathology
8.
Eur J Prev Cardiol ; 21(5): 559-65, 2014 May.
Article in English | MEDLINE | ID: mdl-23253746

ABSTRACT

BACKGROUND: Cross-sectional investigation between presence of antibodies and coronary artery calcification (CAC) in past studies has shown no relationship, but progression over time has not been investigated. The objective of this study was to determine the relationship between presence of Chlamydia pneumoniae antibodies and progression of CAC and ankle-brachial index (ABI). DESIGN: The Multiethnic Study of Atherosclerosis (MESA) is a prospective population-based cohort of racially and ethnically diverse male and female participants recruited from six communities in the USA, age 45-84 years, free of clinical cardiovascular disease at baseline. METHODS: The main outcomes were progression of mean CAC and ABI between exams 1 (2000-02) and 3 (2004-05) (median follow-up of 3.13 years) by C. pneumoniae antibody. Multivariate models adjusting for demographics, obesity, smoking, alcohol use, and physical activity were computed. RESULTS: Of 2223 subjects analysed, 76% were positive for C. pneumoniae antibodies. Progression of CAC was significantly higher in the antibody-positive group (93.8 vs. 78.2 agatston units, p = 0.02) and in antibody-positive subjects with CAC ≥10 at baseline (216.5 vs. 178.6, p = 0.02) than antibody-negative group. Smoking and body mass index ≥30 kg/m(2) both had interactions with presence of C. pneumoniae yielding significantly greater CAC progression. Progression of ABI did not significantly differ by C. pneumoniae antibody status in models adjusted for covariates. CONCLUSIONS: C. pneumoniae antibodies are related to progression of CAC, particularly in individuals with CAC present at baseline. This provides evidence that certain groups are at higher risk of atherosclerotic progression and may be useful for risk stratification and treatment.


Subject(s)
Chlamydophila Infections/epidemiology , Chlamydophila pneumoniae/pathogenicity , Coronary Artery Disease/epidemiology , Vascular Calcification/epidemiology , Aged , Aged, 80 and over , Antibodies, Bacterial/blood , Chlamydophila Infections/blood , Chlamydophila Infections/diagnosis , Chlamydophila Infections/microbiology , Chlamydophila pneumoniae/immunology , Comorbidity , Coronary Artery Disease/blood , Coronary Artery Disease/diagnosis , Coronary Artery Disease/microbiology , Cross-Sectional Studies , Disease Progression , Female , Humans , Linear Models , Male , Middle Aged , Multivariate Analysis , Obesity/epidemiology , Prognosis , Prospective Studies , Risk Assessment , Risk Factors , Smoking/adverse effects , Smoking/epidemiology , Time Factors , United States/epidemiology , Vascular Calcification/blood , Vascular Calcification/diagnosis , Vascular Calcification/microbiology
9.
Nephrol Dial Transplant ; 26(11): 3436-9, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21965584

ABSTRACT

Biomineralization at pathological extraosseous sites (i.e. vasculature and soft tissues) is associated with increased morbidity and mortality. So-called 'nanobacteria' have been described as pathogenic agents causing many diseases including calcification. Initially, their appearance, and having a content consisting of nucleic acids plus proteins and properties of growing structures, suggested that they were living organisms. However, it could be demonstrated that the so-called nanobacteria were in fact mineralizing nanoparticles that contain mineral and non-mineral compounds, that these particles bind to charged molecules and that supersaturation enables in vitro growth of these nanoparticles. Recent data indicate that nanoparticles consisting of protein-mineral complexes can be seen both in vitro and in vivo as precursors of matrix calcification.


Subject(s)
Bacterial Infections/microbiology , Bacterial Infections/prevention & control , Calcifying Nanoparticles , Minerals/metabolism , Vascular Calcification/metabolism , Vascular Calcification/microbiology , Bacteria/growth & development , Bacteria/isolation & purification , Bacteria/metabolism , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...